The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients.
Topics: ALS, Phase III, neural stem cells, multiple sclerosis, stemsaveblog, Brain, clinical trials, Debilitating Diseases, Stemcells, autologousstemcells, Amyotrophic lateral sclerosis, Neurodegenerative disease
Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition.
Topics: Heart Valve, Phase III, Heart, stemsaveblog, Heart Failure, Pediatric Congenital Heart Disease, clinical trials, Debilitating Diseases, Stemcells, hypoplastic left heart syndrome, Heart Attack, autologousstemcells, heart disease
In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission.
In a recent clinical study conducted in Beijing, researchers are testing a treatment for patients suffering from systemic lupus erythematosus by administering autologous [the patient’s own] mesenchymal stem cells. The researchers aim to capitalize on the unique abilities of MSCs to not only differentiate into a multitude of different cell types, but to reduce the autoimmune attack in patients affected by lupus as well.
A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans. 27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection.
Topics: limbs, Phase III, traumatic brain injuries, neural stem cells, multiple sclerosis, stemsaveblog, clinical trials, Debilitating Diseases, Phase II, Stemcells, autologousstemcells, Neurodegenerative disease
Researchers at Sanford-Burnham Medical research institute have developed a potential method of regenerating autologous [the patient’s own] stem cells to repair damaged muscle tissue in patients suffering from muscle-degenerative diseases. The scientists found that the inhibition of protein STAT3 results in the replenishment of the body’s muscle stem cells, which in turn repair the muscles that are damaged by age, cancer, and diseases such as muscular dystrophy.
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas.
Topics: Muscular Dystrophy, ALS, Parkinson's, Phase III, multiple sclerosis, Heart, stemsaveblog, Joints, Alzheimer's, burn injuries, Diabetes, Acute Myocardial Infarction, Brain, Heart Failure, clinical trials, Bone, Debilitating Diseases, Phase II, Arthritis, Stemcells, Teeth, autologousstemcells, cartilage, Amyotrophic lateral sclerosis, Brain Tumors, Blindness
In recent clinical trials, researchers at the National University of Ireland Galway have successfully utilized adult stem cells to treat patients with osteoarthritis. The treatment involves recovering the patients’ own [autologous] stem cells and then injecting the stem cells into cartilage to stimulate the regeneration of lost tissue.
Topics: osteoporosis, Fingers, Phase III, Bone loss, stemsaveblog, Joints, knee replacement, clinical trials, Bone, Debilitating Diseases, Arthritis, Stemcells, Feet, Rheumatoid Arthritis, Hip replacement, Knee, hip, autologousstemcells, cartilage, Cartilage degradation
Researchers at the Cedars-Mt. Sinai Regenerative Medicine Institute, led by Dr. Robert H. Baloh, have devised a method to study and develop potential treatments for Amyotrophic Lateral Sclerosis [ALS] by utilizing patients’ stem cell-derived neurons. In an example of what is referred to as translational genomics, researchers extract autologous (the patient’s own) stem cells, correct the defective gene causing the disease, and then, in a potential treatment protocol, transplant the cells back into the patient to reverse neural degeneration.
Researchers at the University of California, San Diego are set to begin clinical trials to test the safety and effectiveness of a neural stem cell transplant designed to treat spinal cord injuries. In an animal model, the stem cells were able to regenerate the nerves across the site of injury, resulting in the restoration of mobility in the legs.